Navigation Links
No Clear Winner in Diabetes Treatment Trial
Date:9/21/2007

Patient needs may dictate which combo of drugs plus insulin works best, researchers say

FRIDAY, Sept. 21 (HealthDay News) -- A study designed to tell which insulin-plus-drug regimen might best control type 2 diabetes has produced disappointing preliminary results, with none of the three strategies tested coming out on top.

"What this shows is that none of the strategies in the study can be recommended" as being superior to the other, said Dr. Graham T. McMahon, an assistant professor of medicine at Brigham and Women's Hospital in Boston, and co-author of an editorial accompanying the report, published online Friday in the New England Journal of Medicine.

Instead, he said, the insulin regimen would probably have to be tailored to each patient, McMahon said.

The report was released early, because the preliminary, one-year results of the four-year study are being presented at a meeting of the European Association for the Study of Diabetes, in Amsterdam.

The study, led by British diabetes specialists at the University of Oxford, included 708 participants with type 2 diabetes. Type 2 diabetes, which affects about 95 percent of diabetics, typically occurs in adulthood and is often tied to obesity.

All of the trial participants were given maximum doses of two diabetes drugs, metformin and sulfonylurea, and a different regimen of injected insulin three times a day, two times a day or just once a day. The once-a-day group got an extra dose if deemed necessary.

The goal was to reduce blood levels of glycolated hemoglobin, which forms when sugar enters blood cells, to 6.5 percent or less.

The results overall were not impressive: The treatment goal was achieved by just 23.9 percent of those getting insulin three times a day, 17 percent of those getting insulin twice a day and 8.1 percent of those in the once-a-day group, the researchers reported.

The greater success rate in the two- and three-times-a-day regimen had a down side, the team noted, since it was also accompanied by an increased incidence of weight gain and low blood sugar levels, the report said.

Still, the results indicated that "the best thing to be done is to follow current guidelines," McMahon said. That means "using long-acting drugs and adding insulin either once, twice or three times a day," he said, depending on each patient's particular needs.

What the new data "suggests to the doctor is that if you are serious about controlling diabetes, you should be willing to use the more complex method," added Dr. Larry Deeb, clinical professor of pediatrics at the University of Florida and immediate past president of the American Diabetes Association.

Diabetes control "is hard work for doctor and patient," Deeb said, and "family doctors have got to learn to give insulin the way we endocrinologists do." Deeb is located in Tallahassee, Fla., where the ratio of endocrinologists is 1 to 75,000 inhabitants, he noted.

Family doctors can handle type 2 diabetes, McMahon said, but it is best if they do not work alone. "An endocrinologist, nutritionist and nurse-educator should cooperate," he said.

Because type 2 diabetes is a major risk factor for heart disease, attention should be paid not only to blood sugar levels but also to other coronary risk factors, such as blood pressure and cholesterol levels, McMahon said.

What lies ahead for the British study is uncertain, McMahon said. "They are going to next look at what happens when the first steps fail," he said.

More information

For more on type 2 diabetes, consult the American Diabetes Association.



SOURCES: Graham T. McMahon, M.D., assistent professor, medicine, Brigham and Women's Hospital, Boston; Larry Deeb, M.D., clinical professor, pediatrics, University of Florida, Tallahassee; Sept. 21, 2007, early online release, New England Journal of Medicine; Sept. 21, 2007, presentation, annual meeting, European Association for the Study of Diabetes, Amsterdam, the Netherlands


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. British Doctor cleared of murder
3. Benefits of Vitamin Supplements Unclear
4. Chemicals in clear plastics can cause learning difficulties
5. Spray on contraceptive clears Phase I trial
6. Cancer risk among nuclear industry workers
7. Nuclear magnetic resonance spectroscopy aids in mapping protein structure
8. A Novel Method Of Detection Of High Nuclear Grade Localized Renal Cell Carcinoma
9. 21 Women With Breast Cancer Given All Clear By Radiologist
10. Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No
11. The Decks Cleared For HRT - Safe for Menopause Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... NEW ORLEANS, La. (PRWEB) , ... July 21, ... ... tool to allow 4th-year medical students improve their chances of acceptance to a ... particularly for those who have earned degrees outside the U.S. , According to ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is proud of ... her research center at Bio-Logic Aqua Research® Water Life Science®, has been released ... of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... insight into why concussion rates are on the rise, say researchers presenting their ... today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns of ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: